XML 20 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Equity Method Investment
9 Months Ended
Sep. 30, 2023
Equity Method Investment  
Equity Method Investment

5. Equity Method Investment

As of September 30, 2023 and December 31, 2022, the Company’s ownership interest in Angel was approximately 49.7%, excluding 7% of Angel’s equity reserved for issuance under the Angel ESOP. The Company recognized its share of losses in Angel for the total amount of $0.9 million and $3.9 million as loss from equity method investment on the consolidated statement of operations for the three and nine months ended September 30, 2023, respectively.

Summary Financial Information

Summary financial information for Angel Pharmaceuticals is as follows:

As of

As of

Balance Sheet Data

    

September 30, 2023

December 31, 2022

 

(in thousands)

Current assets

$

18,765

$

29,062

Non-current assets

 

1,329

 

1,652

Current liabilities

 

1,613

 

6,293

Non-current liabilities

 

686

 

985

Stockholders' equity

17,795

23,436

Three Months Ended

Nine Months Ended

September 30,

September 30,

Statement of Operations Data

    

2023

2022

2023

2022

 

(in thousands)

Revenue

$

$

$

$

Gross Profit

 

 

 

 

Net loss

(1,016)

(3,204)

(4,565)

(6,402)

Share of loss from investments accounted for using the equity method

 

(865)

 

(2,730)

 

(3,880)

 

(5,367)